Evidence map›Paper›PMID 36195679›Full record

ArticleAnnals of hematology2022

Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.

Kazuki Sakatoku, Sung-Won Kim, Hiroshi Okamura, Minoru Kanaya, Koji Kato, Satoshi Yamasaki, Naoyuki Uchida, Hikaru Kobayashi, Takahiro Fukuda, Nobuyuki Takayama and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 3 countries.

Kazuki SakatokuHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Sung-Won KimDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. skim@ncc.go.jp.ORCID http://orcid.org/0000-0003-4938-3340
Hiroshi OkamuraHematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Minoru KanayaDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Koji KatoHematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Satoshi YamasakiDepartment of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Nobuyuki TakayamaDepartment of Hematology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Hideyuki NakazawaDepartment of Hematology, Shinshu University School of Medicine, Matsumoto, Japan.
Masatoshi SakuraiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Takashi IkedaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
Tadakazu KondoDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Toshihiro MiyamotoHematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Takafumi KimuraPreparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Eisei KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Kyushu University Hospital · JPOsaka City University · JPAichi Medical University · JPHiroshima University · JPJapanese Red Cross Society, Japan · JPKawasaki Medical School · JPKeio University · JPKobe City Medical Center General Hospital · JPKyorin University · JPKyoto University Hospital · JPKyushu University Beppu Hospital · JPNagano Red Cross Hospital · JPNational Cancer Center · USOsaka International Cancer Institute · JPOslo University Hospital · NOShinshu University · JPShizuoka Cancer Center · JPToranomon Hospital · JP

Funding

National Cancer Research and Development Fund 2020-A-15
6 · The paper itself

Abstract

We evaluated 413 adult patients with lymphoma who underwent unrelated cord blood transplantation (UCBT) with fludarabine and melphalan (FM)-based reduced-intensity conditioning between 2002 and 2017 to investigate longitudinal changes in outcomes and the optimal melphalan dose and graft-versus-host disease (GVHD) prophylaxis regimen. Outcomes were compared between FM80/100 (melphalan dose: 80 or 100 mg/m

Indexed as

Cord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationLymphomaAdultCalcineurin InhibitorsHumansMelphalanMethotrexateMycophenolic AcidNeoplasm Recurrence, LocalTransplantation ConditioningVidarabineCalcineurin InhibitorsfludarabineMelphalanMethotrexateMycophenolic AcidVidarabineCord blood transplantationGraft-versus-host disease prophylaxisLymphomaMelphalan doseReduced-intensity conditioning

Identifiers

PMID36195679
OpenAlexW4301370419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.